Results 61 to 70 of about 519,893 (158)

IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
IntroductionSince the COVID-19 outbreak, specific mRNA-based anti-SARS-CoV-2 vaccines have been developed and distributed worldwide. Because this is the first time that mRNA vaccines have been used, there are several questions regarding their capacity to
Sergio Gil-Manso   +76 more
doaj   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

open access: yesVaccines, 2022
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2.
Farah M. Shurrab   +13 more
doaj   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza   +12 more
wiley   +1 more source

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

open access: yesInfectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv   +3 more
doaj   +1 more source

Chemical and Biological Determinants of PEG‐Lipid Shedding From Therapeutic Nanoparticles

open access: yesSmall, EarlyView.
PEG‐lipids play a central role in governing lipid nanoparticle stability, targeting, and function. However, PEG‐lipids can “shed” from the nanoparticle surface in biological environments, with the extent and kinetics of shedding influenced by chemical and biological factors.
Ethan P. Cisneros   +2 more
wiley   +1 more source

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context

open access: yesEClinicalMedicine
Summary: Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series ...
Amparo L. Figueroa   +13 more
doaj   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner   +2 more
wiley   +1 more source

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. [PDF]

open access: yes, 2023
OBJECTIVE: To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. DESIGN: Matched cohort study, emulating a comparative effectiveness trial.
Parker, Edward PK   +39 more
core   +1 more source

IMUNOGENICIDADE DE UM PRIMEIRO REFORÇO COM BNT162B2 OU MRNA-1273 DE DOSE COMPLETA: UM ESTUDO RANDOMIZADO EM ADULTOS ≥75 ANOS (EU-COVAT-1) DO CONSÓRCIO VACCELERATE

open access: yesBrazilian Journal of Infectious Diseases, 2023
Introdução: A vacinação continua sendo crucial para a proteção contra a infecção grave pelo SARS-CoV-2, especialmente na população idosa. Métodos: Avaliamos, em um estudo de fase II randomizado, controlado, adaptativo e multicêntrico, a segurança e a ...
Jon Salmanton-Garcia   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy